Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted) (2022 - 2025)

InMed Pharmaceuticals (INM) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.51 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 86.29% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$2.88, up 62.2%, while the annual FY2025 figure was -$8.36, 58.49% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.51 in Q4 2025 per INM's latest filing, down from -$0.44 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.39 in Q2 2024 and bottomed at -$15.24 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.04, with a median of -$3.58 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 1838.55% in 2024, down 496.81% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$7.73 in 2021, then surged by 47.56% to -$4.06 in 2022, then rose by 8.51% to -$3.71 in 2023, then decreased by 0.27% to -$3.72 in 2024, then surged by 86.29% to -$0.51 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.51 in Q4 2025, -$0.44 in Q3 2025, and $0.01 in Q2 2025.